The Parisian oncology nanomedicine biotech slips at midday, while the Paris market remains higher. This decline follows a sharp rebound after several weeks of high volatility.
A 5% decline in contrast with the rise of the SBF 120
Nanobiotix trades at €26.70 during the session, down 5.05% from the previous close (€28.12). The stock ranks at the bottom of the SBF 120, with the second-largest decline in the index, behind Alstom, while the index gains 0.4% and the CAC 40 rises 0.46%.
The decline is all the more visible as the stock still shows +3.57% over one week and +5.12% over one month, but -20.82% over three months. This sequence illustrates the stock's nervousness: after the rebound at the end of October, the price is giving back part of the ground it had gained.
Nanobiotix is listed both in Paris and on the Nasdaq (ADS NBTX, 1 ADS for 1 share), a dual listing whose movements carry over from one exchange to the other.
The 20-day moving average at €23.78 holds, the 50-day at €28.11 remains out of reach
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock remains 12.3% above its 20-day moving average, a sign that the October rebound has not been erased.
On the other hand, it trades below the 50-day moving average (a 5% gap), which the previous day's price had crossed, and remains below the 200-day moving average at €29.24. The RSI at 51 is neutral: the day's decline does not push it into oversold territory.
On the company side, the latest half-year results, published on September 24, 2026, show cash of €110.9 million, which Nanobiotix says is sufficient to fund its operations until 2029. The support at €18.85 and the resistance at €30.36 frame the technical range to watch in the coming sessions.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
